Christopher R. Cline, CHIEF FINANCIAL OFFICER at Travere Therapeutics, Inc. (TVTX), sold 8,327 shares at $28.85 ($349K) on 2026-04-13, disclosed to the SEC on 2026-04-15.
Scheduled sale ($349k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $28.85 | 65 | $2K | 0.5% |
| 2 | $41.07 | 9 | $370 | 0.1% |
| 3 | $41.93 | 7,239 | $304K | 87.0% |
| 4 | $42.61 | 1,014 | $43K | 12.4% |
| Total | $41.91 avg | 8,327 | $349K | 100% |
| Filing → |
| TVTX | SELL | 2026-05-06 | $115K | — | Filing → |
| TVTX | SELL | 2026-02-05 | $56K | — | Filing → |
| TVTX | SELL | 2026-02-03 | $233K | — | Filing → |